Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score

Journal of Medical Economics

Volumn 14, Issue 5, 2011, Pages 609-616

  Sullivan, Sean D ^a   Garrison Jr , Louis P ^a   Rinde, Harald ^b   Kolberg, Janice ^c   Moler, Edward J ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BioBridge Strategies ^*  (Switzerland)

^c Tethys Bioscience   (United States)

Author keywords

Cost effectiveness; Diabetes health care costs; Markov model; Prevention and control

Indexed keywords

GLUCOSE; METFORMIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DIET RESTRICTION; DISEASE COURSE; FASTING PLASMA GLUCOSE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMPAIRED FASTING GLUCOSE; INCIDENCE; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDX DIABETES RISK SCORE; PREVENTIVE MEDICINE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; UNCERTAINTY; UNITED STATES; VALIDATION STUDY;

BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT;

EID: 80052732370     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.602160     Document Type: Article

References (27)

1. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic betacell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796-803
2. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368: 1096-105
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403
4. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
5. National Diabetes Information Clearinghouse, National Diabetes Statistics, 2007. NIH Publication No. 08-3892. Available at: Http://diabetes.niddk. nih.gov/DM/PUBS/statistics/DM-Statistics.pdf [Last accessed 29 September 2010]
6. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009;13:1-7
7. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007;30:228-33
8. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33:S11-61
9. Urdea M, Kolberg J, Wilber J, et al. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol 2009; 3:748-55
10. Kolberg JA, Jorgensen T, Gerwien RW, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009;32:1207-12
11. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-19
12. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: Cost effectiveness analysis. BMJ 2008;336:1180-5
13. Trogdon JG, Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care 2008;31:2307-11
14. Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Population Health Management 2009;12:103-10
15. Zhang Y, Dall TM, Mann SE, et al. The economic costs of undiagnosed diabetes. Population Health Management 2009;12:95-101
16. Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304-21
17. Nichols GA, Brown JB. Higher medical care costs accompany impaired fasting glucose. Diabetes Care 2005;28:2223-9
18. Boudreau DM, Malone DC, Raebel MA, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord 2009;7:305-14
19. Nichols GA, Arondekar B, Herman WH. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 2008;14:791-8
20. Nichols GA, Arondekar B, Herman WH. Medical care costs one year after identification of hyperglycemia below the threshold for diabetes. Med Care 2008;46:287-92
21. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66
22. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press, 2008
23. Rhee MK, Herrick K, Ziemer DC, et al. Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care 2009;33:49-54
24. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64
25. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32
26. Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults. Arch Intern Med 2007;167:1068-74
27. Collins GS, Altman DG. External validation of the QDScore for predicting the 10-year risk of developing type 2 diabetes. Diabetic Med 2011; 28:599-607